We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
In the latest close session, Recursion Pharmaceuticals (RXRX - Free Report) was down 4.64% at $4.73. The stock's performance was behind the S&P 500's daily gain of 0.03%. At the same time, the Dow lost 0.58%, and the tech-heavy Nasdaq gained 0.28%.
The biotechnology company's shares have seen an increase of 12.73% over the last month, surpassing the Medical sector's loss of 0.01% and the S&P 500's gain of 0.6%.
The upcoming earnings release of Recursion Pharmaceuticals will be of great interest to investors. The company is predicted to post an EPS of -$0.28, indicating a 47.17% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $25.5 million, up 460.44% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.59 per share and a revenue of $64.62 million, representing changes of +5.92% and 0%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Recursion Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 5.08% increase. Right now, Recursion Pharmaceuticals possesses a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
In the latest close session, Recursion Pharmaceuticals (RXRX - Free Report) was down 4.64% at $4.73. The stock's performance was behind the S&P 500's daily gain of 0.03%. At the same time, the Dow lost 0.58%, and the tech-heavy Nasdaq gained 0.28%.
The biotechnology company's shares have seen an increase of 12.73% over the last month, surpassing the Medical sector's loss of 0.01% and the S&P 500's gain of 0.6%.
The upcoming earnings release of Recursion Pharmaceuticals will be of great interest to investors. The company is predicted to post an EPS of -$0.28, indicating a 47.17% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $25.5 million, up 460.44% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.59 per share and a revenue of $64.62 million, representing changes of +5.92% and 0%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Recursion Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 5.08% increase. Right now, Recursion Pharmaceuticals possesses a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.